Site comparison
Amavita Research vs. Baptist Health South Florida: which clinical trial site fits your study?
Sponsors evaluating South Florida cardiovascular trial sites often weigh a dedicated specialist site against a large multi-specialty health system. This page is an educational, side-by-side look at the two operational models so you can match a site to the protocol in front of you.
Amavita Research is a dedicated cardiovascular research site in North Miami Beach. Every active study is cardiovascular - heart failure across the EF spectrum, treatment-resistant hypertension, acute coronary syndrome, structural heart, and peripheral artery disease. The principal investigator team is led by Dr. William W. O'Neill, U.S. TAVR pioneer and National PI on Edwards PARTNER, Protect II, and Protect IV. The on-site Advanced Cardiovascular of Miami ambulatory surgical center handles interventional procedures without referring out.
Baptist Health South Florida is a large multi-specialty health system. As a system, it carries the breadth of a tertiary network: oncology, neuroscience, transplant, orthopedics, women's health, and cardiovascular service lines all coexist. For protocols that require system-wide infrastructure or rare-disease cohorts that span specialties, that breadth is genuinely useful.
The trade-off is operating model. Health systems are typically organized around clinical service lines, with sponsor-facing functions distributed across business development, contracting, regulatory, and study-coordinator teams that report to different leaders. That can be a strength for system-wide programs and a friction point for tightly scoped cardiovascular trials that need a single decision-maker on feasibility, budget, and contract.
Amavita's model is the opposite: one BD contact, one PI team, one cardiovascular SOP set, and audit-ready GCSA-certified processes from day one. For Phase 2-3 cardiovascular protocols where startup speed and enrollment certainty drive program economics, that focus is the differentiator. For multi-specialty programs that genuinely need a system, Baptist Health is a logical partner.
Both models have a role in South Florida cardiovascular research. The right question is not which site is 'better' but which operating model matches the protocol you are trying to enroll on time.
Side-by-side: operating model
Educational summary. We describe the typical multi-specialty health system model and do not make claims about any specific institution's current operations.
| Dimension | Amavita Research | Baptist Health (typical) |
|---|---|---|
| Site type | Dedicated cardiovascular research site | Multi-specialty health system |
| Cardiovascular focus depth | 100% cardiovascular - all studies, all PIs | One service line among many |
| Dedicated cardiovascular ASC | On-site cardiovascular ASC (Advanced Cardiovascular of Miami) | Hospital-based cath lab access |
| BD contact model | Single point of contact: Nereisy Alonso, Sr CRC | Matrixed across system functions |
| Contracting and IRB speed | Days, not quarters; sub-2-week IRB turnaround | Health-system review cycles |
| FDA Diversity Action Plan readiness | Miami patient mix - FDA Diversity Action Plan native | Broad system catchment |
| AI-search readiness | llms.txt + Wikidata + MedicalStudy/JobPosting/FAQ schema | Standard system website |
Frequently asked questions
When does a dedicated cardiovascular site make more sense than a health system?
When the protocol is tightly scoped to cardiology, when enrollment timelines are aggressive, or when the sponsor wants a single accountable decision-maker on feasibility, budget, and contracts. Health systems shine on system-wide or multi-specialty programs.
Does Amavita have access to interventional cardiology procedures on site?
Yes. The affiliated Advanced Cardiovascular of Miami ambulatory surgical center handles interventional cardiovascular and interventional-radiology procedures without external referral.
How fast is contracting at Amavita compared to a typical health system?
Amavita targets contract turnaround in days, not quarters, and sub-two-week IRB submission. Health-system review cycles are typically longer because they pass through more committees.
Can Amavita support FDA Diversity Action Plan requirements?
Yes. The Miami patient population reflects the diversity that FDA Diversity Action Plans now require for Phase 3 cardiovascular trials.
Next step
Schedule a 20-minute capabilities call
One contact. Same-business-day response. Feasibility, budget, contracts, and monitor access all from a single owner.